CFA
XLRN

Clarfeld Financial Advisors’s Acceleron Pharma XLRN Stock Holding History

Clarfeld Financial Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$44K Buy
+1,000
New +$50K 0.04% 103

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Clarfeld Financial Advisors's XLRN Position: Q4 2018 in Review

Clarfeld Financial Advisors opened a new position in Acceleron Pharma (XLRN) in Q4 2018: 1,000 shares worth $44K. The stake represents 0.04% of the portfolio and ranks #103 among its holdings.

162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • Clarfeld Financial Advisors held 1,000 shares of Acceleron Pharma worth $44K as of Q4 2018.
  • Acceleron Pharma was a new Clarfeld Financial Advisors position in Q4 2018.
  • Acceleron Pharma made up 0.04% of Clarfeld Financial Advisors's portfolio in Q4 2018, its #103 holding.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on Clarfeld Financial Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.